305 related articles for article (PubMed ID: 31050713)
1. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
3. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
Kuzbari Z; Bandlamudi C; Loveday C; Garrett A; Mehine M; George A; Hanson H; Snape K; Kulkarni A; Allen S; Jezdic S; Ferrandino R; Westphalen CB; Castro E; Rodon J; Mateo J; Burghel GJ; Berger MF; Mandelker D; Turnbull C
Ann Oncol; 2023 Mar; 34(3):215-227. PubMed ID: 36529447
[TBL] [Abstract][Full Text] [Related]
4. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
[TBL] [Abstract][Full Text] [Related]
5. Mainstreaming informed consent for genomic sequencing: A call for action.
Bunnik EM; Dondorp WJ; Bredenoord AL; de Wert G; Cornel MC
Eur J Cancer; 2021 May; 148():405-410. PubMed ID: 33784533
[TBL] [Abstract][Full Text] [Related]
6. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
7. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
8. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Tsoulos N; Boukovinas I; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Kapsimalis A; Xepapadakis G; Psyrri A; Banu E; Eniu DT; Blidaru A; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
Cancer Genomics Proteomics; 2022; 19(1):60-78. PubMed ID: 34949660
[TBL] [Abstract][Full Text] [Related]
10. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
12. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
13. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
14. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
15. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
16. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
17. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing.
Kuhlen M; Borkhardt A
Eur J Pediatr; 2015 Aug; 174(8):987-97. PubMed ID: 25982339
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
[TBL] [Abstract][Full Text] [Related]
19. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Rasnic R; Brandes N; Zuk O; Linial M
BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
